Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tempus AI, Inc. Class A ( (TEM) ) has provided an announcement.
On January 11, 2026, Tempus AI announced select preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, highlighting a sharp acceleration in both its Diagnostics and Data and Applications businesses. For full year 2025, the company reported estimated revenue of about $1.27 billion, up roughly 83% year over year, including about 30% organic growth excluding its Ambry acquisition; Diagnostics revenue was approximately $955 million, up around 111% year over year on oncology testing volume growth of about 26% and hereditary testing growth of about 29%, while Data and Applications revenue reached roughly $316 million, an increase of about 31% driven by around 38% growth in data licensing. In the fourth quarter of 2025, Tempus generated an estimated $367 million in revenue, also up about 83% year over year, with Diagnostics revenue of roughly $266 million growing about 121% and Data and Applications revenue of approximately $100 million rising around 25% year over year, including an estimated 68% jump in Insights (data licensing) when adjusted for a prior-year AstraZeneca warrant impact. Management characterized 2025 as an exceptional year and said both core product lines are entering 2026 with accelerating growth and improving financial leverage, underscoring Tempus’s strengthening position in AI-driven precision medicine; the company noted these figures are preliminary and unaudited and may change when it reports full fourth-quarter and 2025 results in February 2026.
The most recent analyst rating on (TEM) stock is a Hold with a $80.00 price target. To see the full list of analyst forecasts on Tempus AI, Inc. Class A stock, see the TEM Stock Forecast page.
Spark’s Take on TEM Stock
According to Spark, TipRanks’ AI Analyst, TEM is a Neutral.
Tempus AI’s overall stock score is driven by strong revenue growth and positive developments in the earnings call and corporate events. However, financial performance concerns, challenging valuation, and mixed technical signals weigh on the score.
To see Spark’s full report on TEM stock, click here.
More about Tempus AI, Inc. Class A
Tempus AI, Inc. is a technology company focused on advancing precision medicine through the practical application of artificial intelligence in healthcare. Leveraging one of the world’s largest libraries of multimodal clinical and molecular data and an operating system that makes this data accessible, Tempus provides AI-enabled precision medicine tools to physicians to support personalized patient care while also enabling biopharmaceutical partners to discover, develop and deliver targeted therapeutics.
Average Trading Volume: 5,122,275
Technical Sentiment Signal: Hold
Current Market Cap: $12.16B
See more insights into TEM stock on TipRanks’ Stock Analysis page.